Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001193125-25-233496
Filing Date
2025-10-07
Accepted
2025-10-07 16:15:35
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 10220
2 EX-99.1 ck0000000000-ex99_1.pdf EX-99.1 105892
  Complete submission text file 0001193125-25-233496.txt   158285
Mailing Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517
Business Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517 919-855-2100
TENAX THERAPEUTICS, INC. (Subject) CIK: 0000034956 (see all company filings)

EIN.: 262593535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-58467 | Film No.: 251380022
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 100 CRESCENT COURT SUITE 1620 DALLAS TX 75201
Business Address 100 CRESCENT COURT SUITE 1620 DALLAS TX 75201 214-364-2883
Ikarian Capital, LLC (Filed by) CIK: 0001778253 (see all company filings)

EIN.: 473466768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G